Skip to main content

Table 5 Immunogenicity and seroconversion rates to measles and rubella components of MMR vaccine currently used in Iran

From: Measles and rubella serosusceptibity among population vaccinated with different schedules: the potential impact on measles-rubella elimination in Iran

Author/province
vaccine brand
Years of study No of Subjects Age Lab method Responses Rate MMR (%)
MMR1first dose MMR22second dose
M R M R
Saffar, Mazandaran Razi-Iran [48] 2007 112 12.10 mo ELISA 84.8% 53%
Saffar, Mazandaran
Razi-Iran [49]
2011 249
228
18 m
6 yr
ELISA 74%
6- mo after MMR1
5- yr after MMR1
78.9%
75%6- mo afetr MMR1
66% 5- year after MMR1
94.4% 92.6%
1- mo after MMR2
98.2 87%
1- mo after MMR2
Shamsizadeh, Ahwaz Karaj-Iran Razi Iran [50] 2010–2011 70
90
18 mo
6.5 yr a
ELISA 6- mo after MMR1
42.9%
-
6- mo after MMR190%
-
-
45.6%
-
87.8%a
Tabatabaei, Razi-Iran [51] 2011–2012 240 13.27 mo [12,13,14,15] ELISA 75.8% 73.8%
Zahrari, Baluchestan –Kerman-Hormozgan Razi-Iran [36] 2016 236 > 12 mo ELISA 91.2%b   
Izadi, Baluchestan –Kerman-Hormozgan Razi-Iran [37] 2015 663 30–54 mo   94.6%c
  1. a: One dose of MMR vaccine in addition to two doses of MV at the ages nine and 15 months.
  2. b: Based on strict control of the vaccination administration technique and cold chain control by the researchers.
  3. c: Two- doses of MMR at the ages of 12 and 18 months.